HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+2.02%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.81B
AUM Growth
+$1.81B
(-21%)
Cap. Flow
-$493M
Cap. Flow
% of AUM
-27.27%
Top 10 Holdings %
Top 10 Hldgs %
47.68%
Holding
96
New
23
Increased
8
Reduced
28
Closed
29
Top Buys
| 1 |
Medtronic
MDT
|
$95M |
| 2 |
Danaher
DHR
|
$49.5M |
| 3 |
Elevance Health
ELV
|
$47.1M |
| 4 |
Johnson & Johnson
JNJ
|
$46.6M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$35.8M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$111M |
| 2 |
McKesson
MCK
|
$94.1M |
| 3 |
Welltower
WELL
|
$50.9M |
| 4 |
Cencora
COR
|
$49.9M |
| 5 |
Zimmer Biomet
ZBH
|
$48.4M |
Sector Composition
| 1 | Healthcare | 93.43% |
| 2 | Consumer Discretionary | 2.99% |
| 3 | Financials | 1.09% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$119B
| $158M | 8.62% | 1,530,580 +918,100 | +150% | +$95M |
|
|
2
Bristol-Myers Squibb
BMY
$96B
| $113M | 6.12% | 1,804,550 -1,779,610 | -50% | -$111M |
|
3
Biogen
BIIB
$19.4B
| $109M | 5.92% | 453,400 -13,430 | -3% | -$3.22M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $89.7M | 4.88% | 832,270 -445,958 | -35% | -$48.1M |
|
5
Envista
NVST
$3.52B
| $74M | 4.03% | 1,642,680 -607,292 | -27% | -$27.4M |
|
6
Natera
NTRA
$23.1B
| $70.3M | 3.83% | 752,920 -144,726 | -16% | -$13.5M |
|
|
7
Cencora
COR
$56.5B
| $69.2M | 3.77% | 520,920 -375,760 | -42% | -$49.9M |
|
8
Tenet Healthcare
THC
$16.3B
| $63.9M | 3.48% | 782,180 -302,060 | -28% | -$24.7M |
|
9
Centene
CNC
$14.3B
| $61.8M | 3.36% | 750,270 -232,360 | -24% | -$19.1M |
|
10
Petco
WOOF
$1.12B
| $54M | 2.94% | 2,729,450 -2,215,000 | -45% | -$43.8M |
|
11
Boston Scientific
BSX
$156B
| $53.7M | 2.92% | 1,263,670 -444,011 | -26% | -$18.9M |
|
|
12
Danaher
DHR
$147B
| $49.5M | 2.7% | +150,590 | New | +$49.5M |
|
|
13
Johnson & Johnson
JNJ
$427B
| $47.9M | 2.6% | 279,810 +272,530 | +3,744% | +$46.6M |
|
|
14
Elevance Health
ELV
$71.8B
| $47.1M | 2.56% | +101,560 | New | +$47.1M |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $44.5M | 2.42% | 349,080 -111,710 | -24% | -$14.2M |
|
16
Stryker
SYK
$150B
| $42.5M | 2.31% | 158,940 -63,570 | -29% | -$17M |
|
17
LivaNova
LIVN
$3.08B
| $37.6M | 2.05% | 430,600 -221,550 | -34% | -$19.4M |
|
18
Universal Health Services
UHS
$11.6B
| $37M | 2.02% | 285,620 -63,060 | -18% | -$8.18M |
|
|
19
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $35.8M | 1.95% | +254,230 | New | +$35.8M |
|
20
Cooper Companies
COO
$13.4B
| $33.6M | 1.83% | +80,130 | New | +$33.6M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $33.2M | 1.81% | 409,230 -120,000 | -23% | -$9.73M |
|
22
BioCryst Pharmaceuticals
BCRX
$1.74B
| $32.9M | 1.79% | 2,377,130 -1,472,340 | -38% | -$20.4M |
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $31.2M | 1.7% | 365,737 -80,002 | -18% | -$6.81M |
|
24
Abbott
ABT
$231B
| $28.5M | 1.55% | +202,710 | New | +$28.5M |
|
25
Humana
HUM
$36.5B
| $25.3M | 1.38% | +54,640 | New | +$25.3M |
|